The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, phase II trial of AEZS-108 in chemotherapy refractory triple-negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer.
Stefan Buchholz
Research Funding - Clinical search
Joerg Engel
Employment or Leadership Position - Aeterna Zentaris (I)
Stock Ownership - Aeterna Zentaris (I)
Other Remuneration - travel fundings
Andrew V. Schally
Consultant or Advisory Role - Patents
Research Funding - Aeterna Zentaris
Stephan Seitz
No relevant relationships to disclose
Olaf Ortmann
No relevant relationships to disclose
Guenter Emons
Research Funding - Research Funds
Reshma L. Mahtani
No relevant relationships to disclose
Stefan Gluck
No relevant relationships to disclose
Charles L. Vogel
No relevant relationships to disclose
Alberto J. Montero
No relevant relationships to disclose